DEPARTMENT OF HEALTH AND HUMAN SERVICES **Health Resources and Services Administration** **SAMPLE CLINICAL PERFORMANCE MEASURE** *Example responses are provided for one Clinical Performance Measure - **Diabetes***	**FOR HRSA USE ONLY**	
	Grant Number	**Application Tracking Number**
	XYZ Health Center	000000

Focus Area: Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) *This field contains the content area description for each required performance measure. Applicants will specify focus areas when adding Other performance measures.*	
Performance Measure *This field defines each performance measure.*	Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.
Target Goal Description *In this field, applicants provide a description of the target goal.*	By December 31, 2020, decrease the percentage of adult patients with type 1 or 2 diabetes whose most recent HbA1c is greater than 9% from 65% to 55%.
Numerator Description *In the Clinical Performance Measures, the numerator is the number of patients that meet the criteria identified by the measure (e.g., patients in a specified age range that received a specified service).This field is pre-populated for all required measures.*	Patients whose most recent HbA1c level performed during the measurement period is > 9.0% or who had no test conducted during the measurement period.
Denominator Description *In the Clinical Performance Measures, the denominator is all patients to whom the measure applies (e.g., patients in a specified age range, regardless of whether they received a specified service). This field is pre-populated for all required measures.*	Patients 18-75 years of age with Type 1 or Type 2 diabetes with a medical visit during the measurement period, excluding patients with a diagnosis of secondary diabetes due to another condition and patients who were in hospice care during the measurement period
Baseline Data *In these fields, provide current baseline data. Existing health centers may use data from UDS as applicable.*	**Baseline Year:** 2018 **Measure Type:** Percentage **Numerator:** 2600 **Denominator:** 4000 **Calculated Baseline:** 65%
Projected Data (by December 31, 2020) *This field provides the goal to be met by December 31, 2020.*	55%
Data Source & Methodology *Applicants are required to identify a data source and discuss the methodology used to collect and analyze data.* *For Clinical Performance Measures, applicants must select the data source—EHR, Chart Audit, or Other (please specify)—before describing the methodology.*	**Data Source:** [X] EHR [_] Chart Audit [_] Other (If Other, please specify) : _____ **Data Source and Methodology Description:** Audit of all applicable patient records utilizing EHR system installed in 2010. (Data from 2018 UDS report – data run occurred (1/7/2019).

DEPARTMENT OF HEALTH AND HUMAN SERVICES **Health Resources and Services Administration** SAMPLE CLINICAL PERFORMANCE MEASURE *All applicants are required to complete all fields unless otherwise stated. Example responses are provided for one Clinical Performance Measure - **Diabetes***	**FOR HRSA USE ONLY**	
	Grant Number	**Application Tracking Number**
	XYZ Health Center	000000

Key Factor and Major Planned Action #1 *The Key Factor Type subfield requires applicants to select Contributing and/or Restricting factor categories. Applicants must specify at least one key factor of each type.* *The Key Factor Description subfield provides a description of the factors predicted to contribute to and/or restrict progress toward stated goals.* *The Major Planned Action Description subfield provides a description of the major actions planned for addressing key factors. Applicants must use this subfield to provide planned overarching action steps and strategies for achieving each performance measure.*	**Key Factor Type:** [X] Contributing [_] Restricting **Key Factor Description:** XYZ offers a variety of pharmaceutical assistance programs, including the provision of free, discounted, or generic medications as well as medications through its 340B Federal Drug Pricing arrangement. At least 70% of diabetic patients are on a total of 3 to 8 medications because of co-morbidities and complications. The pharmaceutical assistance programs improve compliance by helping relieve the financial burden of multiple prescribed medications. **Major Planned Action Description:** Increase education and outreach efforts to diabetic patients on using the pharmaceutical assistance programs to improve medication adherence and ultimately improve HbA1c.
Key Factor and Major Planned Action #2	**Key Factor Type:** [_] Contributing [X] Restricting **Key Factor Description:** Integrating Diabetes Collaborative activities into the current work flow remains challenging. The agency-wide team would like to meet more frequently, but providers have little allocated administrative time and full clinical schedules. Any additional system stress negatively affects patient care management. **Major Planned Action Description:** Implement daily huddles with the care team that includes time to share quality dashboard updates and discuss interventions to improve care delivery.
Comments (optional) *If the baseline is zero, provide an explanation and state when baselines will be available.*	